InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Research and development expenses | $1.6M | — | — |
| General and administrative expenses | $10.3M+706.2% | $1.3M+96.5% | $649K |
| Total operating expenses | $11.9M+834.2% | $1.3M | — |
| Loss from operations | -$11.9M-834.2% | -$1.3M-70.6% | -$747K |
| Unrealized gain from changes in fair value of digital assets | $1.8M | — | — |
| Realized gain on sale of digital assets | $4.2M | — | — |
| Trading gains, net | $97 | — | — |
| Foreign currency gains/(losses), net | -$521 | — | — |
| Change in FV of warrant liability | $22K | — | — |
| Change in FV of derivative | $55K | — | — |
| Interest income | $108K+3710.0% | $3K-63.8% | $8K |
| Interest expense | -$283K-140.4% | -$118K-209.2% | -$38K |
| Total other income (expense) | $5.9M+5245.1% | -$115K-279.7% | -$30K |
| Net loss | -$6.0M-331.7% | -$1.4M-78.7% | -$778K |
| Net loss per common share - basic (in Dollars per share) | -$0.55-205.6% | -$0.18-5.9% | -$0.17 |
| Net loss per common share - diluted (in Dollars per share) | -$0.55-205.6% | -$0.18-5.9% | -$0.17 |
| Weighted average common shares outstanding - basic (in Shares) | $10.9M+37.7% | $7.9M+71.9% | $4.6M |
| Weighted average common shares outstanding - Diluted (in Shares) (in Shares) | $10.9M+37.7% | $7.9M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation